

CERTIFICATE OF MAILING BY "EXPRESS MAIL"
I hereby certify that this correspondence is being deposited with the US Postal Services "Express Mail Post Office to Addressee" service under 37 CFR 1.10, Express Mail Label No. EV 346936860 and addressed to MS Patent Application, Commissioner for Patents, Alexandria, VA 22313-1450 on the date shown below:

By:

Carol A. See

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

For: Human Protease and Use of Such
Protease for Pharmaceutical Applications
and for Reducing the Allergenicity of
Non-Human Proteins

[illegible]

Examiner: Unassigned

Information Disclosure Statement

MS Patent Application
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Applicants submit herewith patents, publications or other information (listed on the attached Form PTO-1449 and attached thereto) of which they are aware, that they believe may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 CFR §1.56.

This Information Disclosure Statement:

- (a) ☒ accompanies the new patent application submitted herewith. 37 CFR §1.97(a).
- (b) ☐ is filed within three months after the filing date of the application or within three months after the date of entry into the national stage of a PCT application as set forth in 37 CFR §1.491.
- (c) ☐ as far as is known to the undersigned, is filed before the mailing date of a first Office Action on the merits.

(d) ☐ is filed after the first Office Action and more than three months after the application filing date or PCT national stage date of entry filing but, as far as is known to the undersigned, prior to the mailing date of either a final rejection or a notice of allowance, whichever occurs first, and is accompanied by either the fee (\$180.00) set forth in 37 CFR §1.17(p) or a certification as specified in 37 CFR §1.97(e), as checked below. Authorization to charge Deposit Account No. 07-1048 in the amount of \$180.00 to cover the cost of this Information Disclosure Statement is provided in the Transmittal Letter submitted herewith in duplicate.

(e) ☐ is filed after the mailing date of either a final rejection or a notice of allowance, whichever occurred first, and is accompanied by authorization (in the Transmittal Letter submitted herewith in duplicate) to charge Deposit Account No. 07-1048 the fee (\$180.00) set forth in 37 CFR §1.17(l)(1) and a certification as specified in 37 CFR §1.97(e), as checked below. **This document is to be considered as a petition requesting consideration of the Supplemental Information Disclosure Statement.**

[If either of boxes (d) or (e) is checked above, the following "certification" under 37 CFR §1.97(e) may need to be completed.] The undersigned certifies that:

☐ Each item of information contained in the Information Disclosure Statement was cited in a communication mailed from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.

☐ No item of information contained in this Information Disclosure Statement was cited in a communication mailed from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned after making reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

A copy of the items on Form PTO-1449 is supplied: PCT International Search Report for PCT/_____, filed _____ with attached patents and publications.

☐ each ☒ none ☐ only those listed below:

Those patent(s) or publication(s) which are marked with an asterisk (*) on the attached Form PTO-1449 are not supplied because they were previously cited by or submitted to the Office in a prior application, Serial No. 09/060,854 filed April 15, 1998

A concise explanation of relevance of the items listed on PTO-1449 is:

- ☒ not given
- ☐ given for each listed item
- ☐ given for only non-English language listed item(s)
- ☐ in the form of an English language copy of a Search Report from a foreign patent office, issued in a counterpart application, which refers to the relevant portions of the references.


The Examiner is reminded that a "concise explanation of the relevance" of the submitted prior art "may be nothing more than identification of the particular figure or paragraph of the patent or publication which has some relation to the claimed invention." MPEP §609.

While the information and references disclosed in this Information Disclosure Statement may be "material" pursuant to 37 CFR §1.56, it is not intended to constitute an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

In accordance with 37 CFR §1.97(b), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR §1.56(a) exists. It is submitted that the Information Disclosure Statement is in compliance with 37 CFR §1.98 and MPEP §609 and the Examiner is respectfully requested to consider the listed references.

Respectfully submitted,

Date: *16 September 2003*


Kamrin T. MacKnight
Registration No. 38,230

Genencor International, Inc.
925 Page Mill Road
Palo Alto, CA 94304-1013
Tel: 650 846-5838
Fax: 650 845-6504

INFORMATION DISCLOSURE CITATION

Attorney Docket No.: GC532-C1		Serial No.: Unassigned	
Applicant: David A Estell			
Filing Date: Filed Herewith		Group: Unassigned	
Page <u>1</u> of <u>3</u>		Date of this Submission: September 18, 2003	

US PATENT DOCUMENTS

Examiner's	Document				Sub-	Filing
Initial	Number	Date	Name	Class	Class	Date
	*4,404,128	9/13/83	Anderson	252	546	5/29/81
	*5,612,055	3/18/97	Bedford et al.	424	442	8/16/95
	*5,185,258	2/9/93	Caldwell et al.	435	220	10/19/90
	*5,204,015	4/20/93	Caldwell et al.	252	174.12	10/9/92
	*5,182,204	1/26/93	Estell et al.	435	222	12/11/91
	*5,155,033	10/13/92	Estell et. al.	435	221	1/6/89
	*4,760,025	7/26/88	Estell et al.	435	222	5/29/84
	*5,264,366	11/23/93	Ferrari et al.	435	252.31	11/25/91
	*5,314,692	5/24/94	Haarasilta et al.	424	94.2	5/2/91
	*4,261,868	4/14/81	Hora et al.	252	529	8/879
	*5,147,642	9/15/92	Lotz et al.	424	94.61	12/5/89
	*4,533,359	8/6/85	Kondo et al.	8	128 R	11/5/82
	*4,914,031	4/3/90	Zukowski et al.	435	222	4/10/87

FOREIGN PATENT DOCUMENTS

Examiner's	Document				Sub-	Translation
Initials	Number	Date	Country	Class	Class	Yes/No
	*0 328 229 B1	1/19/94	EP			
	*0 134 267	8/2/89	EP			
	*WO 89/06279	7/13/89	PCT			
	*WO 92/10755	6/25/92	PCT			
	*WO 94/10191	5/11/94	PCT			
	*WO 96/17929	6/13/96	PCT			
	*WO 96/40791	12/19/96	PCT			
	*WO 97/30148	8/21/97	PCT			

Examiner	Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. PTO-1449

INFORMATION DISCLOSURE CITATION

Attorney Docket No.: GC532-C1	Serial No.: Unassigned
Applicant: David A. Estell	
Filing Date: Filed Herewith	Group: Unassigned
Page <u>2</u> of <u>3</u>	Date of this Submission: September 18, 2003

FOREIGN PATENT DOCUMENTS

Examiner's	Document				Sub-	Translation
Initials	Number	Date	Country	Class	Class	Yes/No
	*WO 93 11794A	6/24/93	PCT			
	*WO 99 53038A	10/21/99	PCT			

OTHER DOCUMENTS

Examiner's	
Initials	Author, Title, Date, Pertinent Pages, etc.
	*Barr et al, "cDNA and gene structure for a human subtilisin -like protease with cleavage specificity for paired basic amino acid residues," <i>DNA and Cell Biology</i> , (1991 Jun) 10 (5) pp. 319-28
	*Drenth, Jan et al., « Subtilisin Novo—The Three-Dimensional Structure and Its Comparison with Subtilisin BPN, » Eur. J. Biochem. Vol. 26, pp. 177-181, 1972.
	*Kiefer et al., "Identification of a second human subtilisin -like protease gene in the fes/fps region of chromosome 15," <i>DNA and CELL biology</i> , (1991 DEC) 10 (10) pp. 757-69
	*«Kraut, Joseph, « Serine Proteases : Structure and Mechanism of Catalysis, » Ann. Rev. Biochem., vol. 46, pp. 331-358, 1977.
	*Moeller, G. ed., « Antigenic Requirements for Activation of MHC-Restricted Responses, » Immunological Review, vol. 98, p. 187, Copenhagen, Munksgaard, 1987.
	*Padlan, E. A., "A possible Procedure for Reducing the Immunogenicity of Antibody variable domains while preserving their ligand-binding properties," <i>Molecular Immunology</i> , V. 28, No. 4/05, 1 April 1991, pp. 489-498
	*Philipp, M., et al., « Kinetics of subtilisin and thiolsubtilisin, » Mol. Cell. Biochem., vol. 51, pp. 5-32, 1983.
	*Polgar, Laszlo et al., « Peptic Peptide of Thiolsubtilisin—Analytical Evidence for the Chemical Transformation of the Essential Serine-221 to Cysteine-221, » Biochimica et Biophysica Acta, vol. 667, pp. 351-354, 1981.
	*Poulos, Thomas L., et al., « Polypeptide Halomethyl Ketones Bind to Serine Proteases as Analogs of the Tetrahedral Intermediate, » The Journal of Biological Chemistry, vol. 251, pp. 1097-1103, 1976.
	*Ramnarayan et al., "Antibody humanization predicted by computer graphic analysis," <i>American Biotechnology Laboratory</i> , (1995 Aug) 13 (9) 26, 28, whole document
	*Robertus, Jon D. et al., « An X-ray Crystallographic Study of the Binding of Peptide Chloromethyl ketone Inhibitors to Subtilisin BPN » Biochemistry, vol. 11, no. 13, pp. 2439-2449, 1972.
	*Siezen et al, "Homology modelling and protein engineering strategy of subtilases, the family of subtilisin-like serine proteinases," <i>Protein Engineering</i> , Vol. 4, No. 7, 1 January 1991, pp. 719-737
	*Smeekens, Steven P. et al., « Identification of a Human Insulinoma cDNA Encoding a Novel Mammalian Protein Structurally Related to the Yeast Dibasic Processing Protease Kex2, » The Journal of Biological Chemistry, vol. 265, no. 6, pp. 2997-3000, 1990.
Examiner	Date Considered
Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. PTO-1449	

INFORMATION DISCLOSURE CITATION

Attorney Docket No.: GC532-C1	Serial No.: Unassigned
Applicant: David A. Estell	
Filing Date: Filed Herewith	Group: Unassigned
Page <u>3</u> of <u>3</u>	Dat of this Submission: September 18, 2003

US PATENT DOCUMENTS

Examiner's	Document				Sub-	Filing
Initial	Number	Date	Name	Class	Class	Date

FOREIGN PATENT DOCUMENTS

Examiner's	Document				Sub-	Translation
Initials	Number	Date	Country	Class	Class	Yes/No

OTHER DOCUMENTS

Examiner's	
Initials	Author, Title, Date, Pertinent Pages, etc.
	*Stauffer, C.E., et al., « The Effect on Subtilisin Activity of Oxidizing a Methionine Residue, » The Journal of Biological Chemistry, vol. 244, no. 19, pp. 5333-5338, 1969.
	*Stroud, Robert M., « A Family of Protein-Cutting Proteins, » R. Sci. Amer., vol. 131, pp. 74-88.
	*Svendsen, I.B., « Chemical Modifications of the Subtilisins with Special Reference to the Binding of Large Substrates. A Review, » Carlsberg Res. Comm., vol. 41, no. 5, pp. 237-291, 1976.
	*Tomkinson, Birgitta et al., « Characterization of cDNA for Human Tripeptidyl Peptidase II : The N-Terminal Part of the Enzyme is Similar to Subtilisin, » Biochem., vol. 30, pp. 168-174, 1991.
	*Wright, Christine et al., « Structure of Subtilisin BPN' at 2.5 Å Resolution, » Nature, vol. 221, pp. 235-242, 1969.
	*Copy of PCT Search Report
Examiner	Date Considered
Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	
PTO-1449	